Navigation Links
University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
Date:6/2/2008

time, we are able to watch for sudden, significant changes in the patients' CMI levels, which are predictive of either infection or onset of cellular transplant rejection."

The clinical research team further noted that among 29 patients with persistently low CMI levels (< 100 ng ATP/mL) they observed none of the major consequences reported by other investigators and that low absolute CD4+ T-cell levels did not impede the potential for "strong" ImmuKnow response levels.

About ImmuKnow(R)

ImmuKnow is an immune cell function assay that can detect cell-mediated immunity (CMI) in adult patient populations undergoing immunosuppressive therapy for organ transplantation by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow assays should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. The use of the ImmuKnow assay as described in this study has not been approved or cleared by the FDA. The company may use data from this or similar studies to support a future FDA marketing application for a similar indication.

About Cylex, Incorporated

Cylex(TM) is a privately held global life sciences company and a leader in the development and manufacture of research and in vitro diagnostic products intended to assist in the assessment of immune function. Cylex is the first and only company to offer a patent-protected in vitro diagnostic assay (ImmuKnow) used in the detection of cell-mediated immune function in immune-suppressed organ transplant patient populations. The ImmuKnow assay is increasingly being adopted for use by organ transplant centers throughout the USA and in other countries around the world. The Company's patented technology provides an innovat
'/>"/>

SOURCE Cylex, Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
2. Boston University Biomedical Engineers Find Chink in Bacterias Armor
3. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
4. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
5. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
8. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
9. Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University
10. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
11. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... following is being released by SafeMinds ( www.SafeMinds.org ): ... has publicly denied a vaccine-autism link, while at the ... been awarding damages for vaccine injury to children with ... on verifiable government data, breaks ground in the controversial ...
... Perrigo Company (Nasdaq: PRGO ; TASE) today ... relating to fluticasone lotion brought by Nycomed US Inc. by ... of the settlement, Perrigo can launch a generic version of ... certain circumstances. Cutivate® (fluticasone) lotion is indicated ...
Cached Medicine Technology:83 Cases of Autism Associated with Childhood Vaccine Injury Compensated in Federal Vaccine Court 2Perrigo Announces Settlement of Cutivate Lotion Litigation 2
(Date:4/18/2014)... 18, 2014) Benaroya Research Institute at Virginia Mason ... a particular molecule in metastatic breast cancer reduces both ... lung metastases. BRI scientists have found in models of ... by 60 - 80 percent and can keep the ... $1.8 million five-year grant comes from the National Cancer ...
(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2
... , DALLAS, Jan. 11 The American ... effort led by the Department of Health and Human Services ... encourage more Americans to get vaccinated against H1N1. ... people with heart failure or with any cardiovascular disease. Like ...
... researchers suggest , MONDAY, Jan. 11 (HealthDay News) -- A ... genetic variant associated with the aggressiveness of prostate cancer, in ... out cancers that need intensive treatment from those that can ... principle to show that there are variants in the genome ...
... ... , ... Primary care physicians may be able to help increase Americans, willingness to become organ donors ... about end-of-life care, according to a study in the January issue of the Journal of ...
... , , BATESVILLE, Ind., Jan. 11 Hillenbrand, Inc. (NYSE: ... to 1:30 p.m. in New York, N.Y., on Jan. 14, 2010, and ... for Hillenbrand to acquire K-Tron International, Inc. ( KTII). , You are ... hear from and meet members of the Hillenbrand and K-Tron management teams ...
... , FAIRVIEW, Pa., Jan. 11 ... and manufacturer of custom electronic products and systems, today reported results ... , For the fourth quarter of fiscal 2009, the Company ... on sales of $34.1 million, compared to net income of $2.5 ...
... Amounts deemed safe are still too high, researchers say , ... of lead may harm children,s kidneys, say U.S. researchers. , ... per deciliter of blood, according to the U.S. Centers for ... Center study suggests that even levels below 10 micrograms are ...
Cached Medicine News:Health News:American Heart Association Encourages Heart Disease Patients to Get H1N1 Flu Shot in Support of National Influenza Vaccination Week, Jan. 10-16 2Health News:Genetic Marker for Aggressive Prostate Cancer Found 2Health News:Genetic Marker for Aggressive Prostate Cancer Found 3Health News:New Study Says Doctors' Offices -- Not the DMV -- Should Be Where Americans Decide to Become Organ Donors 2Health News:New Study Says Doctors' Offices -- Not the DMV -- Should Be Where Americans Decide to Become Organ Donors 3Health News:New Study Says Doctors' Offices -- Not the DMV -- Should Be Where Americans Decide to Become Organ Donors 4Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 2Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 3Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 4Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 5Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 2Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 3Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 4Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 5Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 6Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 7Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 8Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 9Health News:Very Low Levels of Lead Harm Kids' Kidneys: Study 2
... testing your blood glucose regularly, you want ... possible. Conventional spring-loaded lancet systems often penetrate ... cause painful dilation or tearing of skin ... a precise, linear action that provides greater ...
... Finnpipette Focus from Thermo Labsystems was designed ... Advanced features such as the new ... adjustment on microvolumes help to define this ... pipettes. The new interchangeable handle plate offers ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,410-0) or contact custom...
... digital models cover the range from 2ul to ... Volume lock design prevents inadvertent volume change. ... grip. Whole pipette is autoclavable at 121C(250F). ... all polypropylene. Suitable for one-handed operation. ...
Medicine Products: